(Q37521326)

English

Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).

scientific article published on June 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

1 reference

Europe PubMed Central

Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

0 references

medical oncology

1 reference

based on heuristic

inferred from title

author name string

Joan Albanell

1

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Xavier Andreu

2

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

María José Calasanz

3

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Angel Concha

4

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

José María Corominas

5

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Tomás García-Caballero

6

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

José Antonio López

7

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Fernando López-Ríos

8

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Santiago Ramón y Cajal

9

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Francisco J Vera-Sempere

10

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Ramón Colomer

11

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Miguel Martín

12

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Emilio Alba

13

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Antonio González-Martín

14

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Antonio Llombart

15

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Ana Lluch

16

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

José Palacios

17

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Clinical and Translational Oncology

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

363-375

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

https://scigraph.springernature.com/pub.10.1007/s12094-009-0370-6

0 references

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

1 reference

https://api.crossref.org/works/10.1007%2FS12094-009-0370-6

21 January 2018

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

1 reference

https://api.crossref.org/works/10.1007%2FS12094-009-0370-6

21 January 2018

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 in well differentiated breast cancer: is testing necessary?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 testing in the UK: consensus from a national consultation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The basic biology of HER2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of formalin tissue fixation and processing on immunohistochemistry

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concordance between central and local laboratory HER2 testing from a community-based clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biology of HER2 and its importance in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current perspectives on HER2 testing: a review of national testing guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 testing in the UK: further update to recommendations

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19531451

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12094-009-0370-6

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37521326&oldid=2090634048"